EMA Authorised: Armisarte (previously Pemetrexed Actavis) (pemetrexed diacid monohydrate) — Actavis Group PTC ehf

View source ↗

Summary

Armisarte (pemetrexed diacid monohydrate) has been authorised in the EU for non-small cell lung cancer and mesothelioma; Actavis Group PTC ehf is the marketing …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mesothelioma
• Non-small Cell Lung Cancer

Drugs mentioned

• Armisarte (pemetrexed diacid monohydrate)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Non-Small-Cell Lung;Mesothelioma. MAH: Actavis Group PTC ehf. Decision date: 12/12/2024